Scarica l'app Stockscreener
65.77
2.02%
1.30
Dopo l'orario di chiusura:
65.77
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché HALO Giù?
Forum
Previsione
Halozyme Therapeutics Inc Borsa (HALO) Ultime notizie
Bench International Announces Appointment of Jim Lang to the Board of Directors of Halozyme Therapeutics - PR Newswire
Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443B - Benzinga
Halozyme Therapeutics (HALO): A Fresh Look at Valuation After Board Appointment of Dealmaker Jim Lang - Sahm
Halozyme's Elektrofi Deal: Site-Of-Care Optionality (Rating Upgrade) - Seeking Alpha
Halozyme Therapeutics, Inc. $HALO Shares Bought by HRT Financial LP - MarketBeat
Did Patent Win and Jim Lang’s Arrival Just Shift Halozyme Therapeutics’ (HALO) Investment Narrative? - simplywall.st
BI Asset Management Fondsmaeglerselskab A S Grows Stock Holdings in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Stock Report: What catalysts could drive Halozyme Therapeutics Inc stock higherJuly 2025 Intraday Action & Verified Stock Trade Ideas - moha.gov.vn
Halozyme Elects James Lang to Board of Directors - TipRanks
Smart Money: Is Halozyme Therapeutics Inc stock overvalued by current metricsQuarterly Market Summary & High Yield Stock Recommendations - moha.gov.vn
Halozyme Therapeutics, Inc. $HALO Shares Sold by Gabelli Funds LLC - MarketBeat
First Trust Advisors LP Decreases Stake in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme Therapeutics awards performance-based stock units to CEO By Investing.com - Investing.com Canada
Halozyme Approves Stock Grant for CEO Incentive - TipRanks
Halozyme Therapeutics awards performance-based stock units to CEO - Investing.com
(HALO) Movement as an Input in Quant Signal Sets - news.stocktradersdaily.com
Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term - sharewise.com
Halozyme Therapeutics announces proposed offering of $650M of convertible senior notes due 2031 and 2032 - MSN
Marshall Wace LLP Has $20.24 Million Holdings in Halozyme Therapeutics, Inc. $HALO - MarketBeat
2Xideas AG Sells 62,256 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
James Lang elected to Halozyme Therapeutics board of directors By Investing.com - Investing.com Canada
James Lang elected to Halozyme Therapeutics board of directors - Investing.com
Halozyme Therapeutics Elects New Board Member - TradingView
Jim Lang elected to Halozyme’s board of directors - Investing.com
Jim Lang elected to Halozyme’s board of directors By Investing.com - Investing.com India
Halozyme (NASDAQ: HALO) elects ex-EVERSANA CEO Jim Lang to board of directors - Stock Titan
Halozyme and Quinn Emanuel secure PI against MSD over Keytruda SC - JUVE Patent
Cash per share of Halozyme Therapeutics, Inc. – FWB:RV7 - TradingView
Halozyme wins German injunction blocking Merck’s Keytruda distribution - Indian Pharma Post
Jim Lang Elected to Halozyme's Board of Directors - Sahm
Halozyme granted injunction in Germany barring Merck's subcutaneous Keytruda - MSN
Halozyme Therapeutics (HALO): Reassessing Valuation After Strong Year-To-Date Gains And Recent Momentum Slowdown - Yahoo Finance
Norges Bank Makes New Investment in Halozyme Therapeutics, Inc. $HALO - MarketBeat
American Century Companies Inc. Sells 762,886 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
The Healthcare Sector Is Surging. Here's 1 Stock Every Investor Should Have on Their Radar. - Finviz
Why Is Halozyme Therapeutics (HALO) Down 2.2% Since Last Earnings Report? - MSN
Epoch Investment Partners Inc. Sells 195,366 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme Therapeutics (NASDAQ:HALO) Rating Lowered to "Buy" at Wall Street Zen - MarketBeat
Kennedy Capital Management LLC Has $21.60 Million Stake in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme Therapeutics (NASDAQ:HALO) Receives Sell Rating from The Goldman Sachs Group - MarketBeat
Citizens reiterates Market Outperform rating on Halozyme stock amid legal win - Investing.com
Why Halozyme Therapeutics Inc. stock could rally in 20252025 Trade Ideas & Safe Entry Momentum Stock Tips - Newser
Merck suffers a setback over its new Keytruda formulation in Germany - statnews.com
Halozyme Therapeutics Inc RV7 Stock Analysis and ForecastPrice Action Analysis & The Smart Money Is Buying These Picks - earlytimes.in
Halozyme (HALO) Wins Injunction Against Merck in Germany - GuruFocus
How Halozyme Therapeutics Inc. (RV7) stock behaves in tightening cyclesTrade Risk Summary & Expert Curated Trade Setup Alerts - Newser
0.18%
0.62%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):